Sustainable Enzyme Engineering Will Power Expanding Biopharma Opportunities
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 6 Analysts
Published
10 Aug 25
Updated
16 Aug 25
AnalystHighTarget's Fair Value
US$11.00
72.7% undervalued intrinsic discount16 Aug
US$3.00
1Y
-0.3%7D
7.1%